Active, not recruitingPhase 4NCT06825312
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Studying Encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
- Principal Investigator
- Huanyu Wang, PhD, D(ABMM)Liaoning Chengda Biotechnology CO., LTD
- Intervention
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated(biological)
- Enrollment
- 600 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2031
Study locations (6)
- Jiashan County Center for Disease Control and Prevention, Jiaxing, Zhejiang, China
- Pinghu Center For Disease Control and Prevention, Jiaxing, Zhejiang, China
- Dongyang Center for Disease Control and Prevention, Jinhua, Zhejiang, China
- Yongkang Center for Disease Control and Prevention, Jinhua, Zhejiang, China
- Yuyao Center for Disease Control and Prevention, Ningbo, Zhejiang, China
- Jiangshan Center For Disease Control and Prevention, Quzhou, Zhejiang, China
Collaborators
Zhejiang Provincial Center for Disease Control and Prevention
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06825312 on ClinicalTrials.govOther trials for Encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07332234Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesSpitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
- ACTIVE NOT RECRUITINGNCT06820060Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel PlusQIAGEN Gaithersburg, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineBavarian Nordic
- RECRUITINGPHASE1, PHASE2NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsSK Bioscience Co., Ltd.
- RECRUITINGNCT06368648CoMind Early Feasibility StudyCoMind Technologies Limited
- ACTIVE NOT RECRUITINGPHASE4NCT06678373Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasLiaoning Chengda Biotechnology CO., LTD
- RECRUITINGPHASE2NCT06510426Early Interferon-beta Treatment for West-Nile Virus InfectionTel-Aviv Sourasky Medical Center
- RECRUITINGNCT07191223Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in FranceUniversity Hospital, Strasbourg, France